VERA at a glance
Vera Therapeutics, Inc. (VERA, SEC CIK 1831828) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Vera Therapeutics, Inc. (VERA) shares worth $710.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Fordyce Marshall on September 15, 2026 of 18,500 shares at $37.00 per share.
- In the last 90 days, VERA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$1.3M
- 13F holders
- 27 funds
- $710.4M · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm
- Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments
- Key operational risk from reliance on specialized cybersecurity personnel with 29 and 28 years’ experience in biotech IT and security
- Incident response plan escalates incidents to management and board audit committee, ensuring rapid mitigation and remediation
- Regular management updates and external briefings to monitor and mitigate evolving cybersecurity threats
AI summary of the VERA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $10.3M, versus $0 YoY, entirely from TRUTAKNA sales
- Gross margin 68%, based on $10.3M revenue and $3.3M cost of sales
- Net loss $93.7M vs $80.3M YoY, with operating expenses $106.0M vs $83.9M
- Cash, equivalents and marketable securities $384.0M vs $714.6M at December 31, 2025
- Nine-month operating cash outflow $305.9M vs $171.1M, with $9.6M financing inflow and $75.0M debt draw in October 2026
- Near-term outlook: continued losses and rising R&D, SG&A and capital expenditures, with liquidity expected for at least 12 months
Risk Factors
- Newly heightened commercialization risk: FDA accelerated approval of TRUTAKNA on July 7, 2026 created post-approval study and commercial execution obligations
- Regulatory risk: confirmatory eGFR study failure could trigger accelerated-approval withdrawal after approval based on UPCR results
- Operational risk: limited commercialization experience and newly building sales, market-access, and distribution capabilities
- Competitive risk: Roche’s GAZYVA received FDA Priority Review in July 2026 for pMN, with a decision expected by November 2026
- Financial risk: $150.0 million outstanding under the 2025 Loan Agreement as of October 31, 2026, with covenant-related acceleration exposure
AI summary of the VERA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for period ended September 30, 2026, announced November 5, 2026
- Corporate updates included alongside financial results
Item EX-99.1: Item EX-99.1
- Q3 launch generated $10.3M product revenue and approximately 700 Patient Start Forms, establishing initial commercial traction for TRUTAKNA
- ORIGIN 3 showed eGFR decline of 0.6 versus 5.6 mL/min/1.73m²/year placebo, a 5.0 treatment difference and p<0.0001
Item EX-99.1: Item EX-99.1
- ORIGIN 3 met all prespecified endpoints in 428 patients, supporting TRUTAKNA’s potential transition from accelerated to full approval
- eGFR decline through 104 weeks: -0.6 vs -5.6 mL/min/1.73m²/year, a 5.0 treatment effect with p<0.0001
Item 7.01: Regulation FD Disclosure
- TRUTAKNA met all prespecified endpoints in final ORIGIN 3 efficacy analysis for adults with primary IgA nephropathy
- Positive Phase 3 data strengthens TRUTAKNA’s regulatory and commercial prospects in a disease with progression risk
Item 8.01: Other Events
- ORIGIN 3 met all prespecified endpoints in 428 adults with primary IgAN at risk for progression
- 52-week eGFR decline: 0.1 versus 5.7 mL/min/1.73m², treatment effect 5.6, p<0.0001
Item EX-99.2: Item EX-99.2
- ORIGIN 3 final results support Vera’s planned sBLA submission in Q4 2026 and potential full FDA approval in 2027
- TRUTAKNA improved eGFR by 5.6 mL/min/1.73m at 52 weeks versus placebo, supporting kidney-protection claims
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, released August 10, 2026
- Corporate updates included alongside earnings release
Item EX-99.1: Item EX-99.1
- FDA accelerated approval and U.S. launch make TRUTAKNA Vera’s first commercial product and establish a potential IgAN growth platform
- ORIGIN 3 final efficacy analysis expected Q3 2026, with supplemental BLA submission expected Q4 2026 and potential full approval in 2027
AI summaries of VERA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VERA
Don't miss the next VERA filing
- Alerts as it files. A push when VERA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VERA, by share count.
- Ask anything. An AI agent that reads every VERA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fordyce Marshall | Sell | Sep 15, 2026 | 18,500 | $37.00 |
| Fordyce Marshall | M | Sep 15, 2026 | 18,500 | - |
| Fordyce Marshall | M | Sep 15, 2026 | 18,500 | $2.90 |
| Young Joseph R | M | Sep 11, 2026 | 5,000 | $3.94 |
| Young Joseph R | M | Sep 11, 2026 | 5,000 | - |
| Fordyce Marshall | M | Sep 2, 2026 | 18,500 | $2.90 |
| Fordyce Marshall | M | Sep 2, 2026 | 18,500 | - |
| Fordyce Marshall | Sell | Sep 2, 2026 | 18,500 | $35.12 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$102.0M | -$167.2M | -$315.5M |
| Net Income | -$96.0M | -$152.1M | -$299.6M |
| Balance Sheet | |||
| Total Assets | $175.5M | $655.7M | $734.7M |
| Equity | - | $577.2M | $604.5M |
| ROE | - | -26.4% | -49.6% |
| Per Share | |||
| EPS | $-2.25 | $-2.75 | $-4.66 |
| Cash Flow | |||
| Operating CF | -$92.2M | -$134.7M | -$241.1M |
| CapEx | $63K | $972K | $630K |
Source: XBRL data in Vera Therapeutics, Inc. (VERA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VERA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $710.4M |
| Q2 2026 | 30 | $1.20B |
| Q1 2026 | 30 | $977.2M |
| Q4 2025 | 25 | $1.27B |
| Q3 2025 | 24 | $634.0M |
| Q2 2025 | 25 | $528.0M |
| Q1 2025 | 22 | $265.0M |
| Q4 2024 | 20 | $400.8M |
- Millennium Management+559.6K (+201%)
- Bank of America Corp+362.6K (+61%)
- Ameriprise Financial+145.6K (+251%)
- Dimensional Fund Advisors+122.6K (+23%)
- Fifth Third Bancorp+54.9K (+50%)
- Morgan Stanley−2.11M (-75%)
- T. Rowe Price Group−1.26M (-31%)
- State Street Corp−846.9K (-20%)
- Two Sigma Investments−54.8K (-53%)
- Vanguard Capital Management LLC−44.2K (-2%)
- Franklin Resources+295.6K
- FMR LLC (Fidelity)−2.77M
- Renaissance Technologies LLC−279.5K
- D.E. Shaw & Co−74.5K
- Allstate−6.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 203 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VERA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Jul 9, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jul 7, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VERA SEC filings: frequently asked questions
Are VERA insiders buying or selling?
In the last 90 days, Vera Therapeutics, Inc. (VERA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.3 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VERA stock?
As of September 30, 2026, the largest Vera Therapeutics, Inc. (VERA) holders among the 13F filers tracked by SignalX were BlackRock ($185.0 million), State Street Corp ($106.6 million), T. Rowe Price Group ($88.8 million), Vanguard Capital Management LLC ($87.5 million), Goldman Sachs Group ($45.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in VERA's latest 10-K?
In the 10-K filed February 26, 2026, Vera Therapeutics, Inc. (VERA) flagged: Cybersecurity risk exposure from IT systems or third-party partners, potential regulatory investigations, litigation, fines, business disruption, reputational harm. Oversight by audit committee and Cybersecurity Risk Management Committee using manual/automated tools and third-party assessments. (AI summary of the Risk Factors section.)
What did VERA report in its latest 8-K?
Vera Therapeutics, Inc. (VERA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026, announced November 5, 2026.
What are the latest VERA SEC filings?
Vera Therapeutics, Inc. (VERA) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on September 17, 2026.
What is VERA's SEC CIK number?
Vera Therapeutics, Inc. (VERA)'s SEC Central Index Key (CIK) is 1831828. EDGAR lists every VERA filing under that number.
Ask anything about VERA
The research agent reads VERA's filings, financials, insider trades and 13F holders, then answers with sources.